Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 105Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 112Neoplasms 73Carcinoma, Non-Small-Cell Lung 36Carcinoma, Renal Cell 35Prostatic Neoplasms 34Colorectal Neoplasms 34Lung Neoplasms 31Melanoma 17Multiple Myeloma 15Ovarian Neoplasms 13Urinary Bladder Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 11Lymphoma, Follicular 11Colonic Neoplasms 11Stomach Neoplasms 10Lymphoma 10Kidney Neoplasms 10Hematologic Neoplasms 10Rectal Neoplasms 9Arthritis, Rheumatoid 9Recurrence 8Papillomavirus Infections 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Pancreatic Neoplasms 7Neoplasms, Plasma Cell 7Lymphoma, Large B-Cell, Diffuse 7COVID-19 7Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Has results × Carcinoma, Transitional Cell × Clear all
NCT04822350 2026-04-02

AVENANCE

Pfizer

Completed
596 enrolled 43 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05431777 2025-04-01

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
79 enrolled 20 charts
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡